Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial

ABSTRACT Background: Decreased initiation of activities is a common symptom in Alzheimer's disease (AD) and creates significant burden for carers, yet little is known about how patients, carers and treating physicians describe this problem. Methods: This is a secondary, qualitative analysis of video-recorded, semi-structured and open-ended interviews with the 130 community-dwelling patients with mild-to-moderate AD from the Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) study – a four-month, randomized, placebo-controlled trial of galantamine. Interviews were coded and organized using Atlas.ti. By applying a framework analysis approach, patient/carer descriptions of dementia-related decreased initiation of usual tasks and activities were categorized and summarized. Results: Decreased initiation of instrumental activities of daily living (IADLs) and/or leisure and social activities was reported in 85/130 patients at baseline, 71 (84%) of whom specifically targeted increased initiation as a goal of treatment. The most common manifestations of decreased initiation were initiating only with prompting (55%), and no longer initiating but willing to engage in the activity (42%; note that these groups can overlap). Many patients were also described as having less interest (44%) or impaired performance (34%) in the activity in which decreased initiation was noted. Coping strategies were employed by 69/85 carers, most commonly verbal prompts to begin an activity. Conclusion: Decreased initiation is a common and problematic symptom in people with mild-to-moderate Alzheimer's disease who seek treatment for dementia. Information offered voluntarily about interest in or ability to perform activities which are initiated less often gives additional data compared with routine questioning about initiation of function. This is a potentially rich area for the elucidation of disease and treatment effects.

[1]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[2]  R. Marin.  Differential diagnosis and classification of apathy. , 1990, The American journal of psychiatry.

[3]  The development of a care-giving burden scale. , 1994, Age and ageing.

[4]  The Development of a Care-giving Burden Scale , 1994 .

[5]  S. Gauthier,et al.  Functional Disability in Alzheimer's Disease , 1997, International Psychogeriatrics.

[6]  S H Ferris,et al.  Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.

[7]  J. Morris,et al.  Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) , 1997 .

[8]  J. Morris,et al.  Validity and Reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change , 2017 .

[9]  S. Gauthier,et al.  Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. , 1999, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[10]  Bruno Dubois,et al.  CONFABULATION, EXECUTIVE FUNCTIONS, AND SOURCE MEMORY IN ALZHEIMER'S DISEASE , 1999 .

[11]  W H Isbister,et al.  Qualitative research in health care , 2000, BMJ : British Medical Journal.

[12]  Qualitative Analysis of the Clinician Interview-Based Impression of Change (Plus): Methodological Issues and Implications for Clinical Research , 2000, International Psychogeriatrics.

[13]  Sue Ziebland,et al.  Analysing qualitative data , 2000, BMJ : British Medical Journal.

[14]  S. Starkstein,et al.  Syndromic validity of apathy in Alzheimer's disease. , 2001, The American journal of psychiatry.

[15]  Patterns of Clinically Detectable Treatment Effects with Galantamine: A Qualitative Analysis , 2002, Dementia and Geriatric Cognitive Disorders.

[16]  Steven G Potkin,et al.  The ABC of Alzheimer's Disease: ADL and Improving Day-to-Day Functioning of Patients , 2002, International Psychogeriatrics.

[17]  L. Spencer,et al.  Qualitative data analysis for applied policy research , 2002 .

[18]  Stephen Salloway,et al.  Executive dysfunction and apathy predict functional impairment in Alzheimer disease. , 2003, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[19]  D. Royall,et al.  Executive dyscontrol in normal aging: Normative data, factor structure, and clinical correlates , 2003, Current neurology and neuroscience reports.

[20]  L. Thal,et al.  Executive dysfunction in Alzheimer disease. , 2004, Archives of neurology.

[21]  K. Andersen,et al.  Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia , 2004, Health and quality of life outcomes.

[22]  R. Bullock,et al.  Executive Function: The Core Feature of Dementia? , 2004, Dementia and Geriatric Cognitive Disorders.

[23]  E. Murphy,et al.  A response to 'Quality in qualitative evaluation: a framework for assessing research evidence' , 2004 .

[24]  S. Gauthier,et al.  Trial Designs and Outcomes in Dementia Therapeutic Research , 2005 .

[25]  Thomas J. Kiresuk,et al.  Goal attainment scaling: A general method for evaluating comprehensive community mental health programs , 1968, Community Mental Health Journal.

[26]  S. Fay,et al.  Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial , 2006, Canadian Medical Association Journal.

[27]  B. Dubois,et al.  Neuropsychological Performance in Mild Cognitive Impairment with and without Apathy , 2006, Dementia and Geriatric Cognitive Disorders.

[28]  Kenneth Rockwood,et al.  The measuring, meaning and importance of activities of daily living (ADLs) as an outcome , 2007, International Psychogeriatrics.

[29]  S. Fay,et al.  Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. , 2007, Neurology.